CClinicalTrials.gg
Sign In
Status unknownNCT05083286Updated Oct 27, 2021

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

An Early Phase 1 interventional study of OnabotulinumtoxinA in Glabellar Frown Lines, sponsored by Clinical Testing of Beverly Hills. Status unknown at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by Clinical Testing of Beverly Hills · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of BOTOX in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

Read the detailed description

This study involves a blinded, randomized, parallel-group design. The aim of this study is to evaluate the duration response of BOTOX in subjects with moderate to severe dynamic glabellar lines at the approved on-label dose of 20 U, however comparing the use of highly Concentrated On Label Dose (COLD) to the On Label Dose and concentration (OLD). The COLD concentration is defined as 4 Units per 0.02 mL and the OLD concentration is defined as 4 Units per 0.1 mL.

The total BOTOX dose will be 20U divided into 5 injections for both study groups. However, the injection volume will differ for the two study groups, such that the OLD (4 U per 0.1 mL) group will receive a total of 0.5 mL and the COLD (4 U per 0.02 mL) group will receive a total of 0.1mL.

02

Conditions studied

  • Glabellar Frown Lines

Keywords

  • wrinkles
  • onabotulinumtoxinA
03

In context

Lead sponsor

Clinical Testing of Beverly Hills is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • At least 18 years of age at the time of signing the informed consent.
  • Overtly healthy as determined by medical evaluation (includes: medical history, physical examination, and vital signs).
  • Subjects have moderate or severe dynamic glabellar lines on maximum frown as assessed with the Facial Wrinkle Scale.
  • Female sex.
  • Female subjects willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. A female subject is eligible to participate if she is not pregnant (has a negative urine pregnancy result at Day 1 prior to treatment), is not breastfeeding, and at least one of the following conditions applies: 1) not a female of childbearing potential or 2) a female of childbearing potential who agrees to follow the contraceptive guidance.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
  • Written informed consent from the subject has been obtained prior to any study-related procedures.
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information)
  • Able, as assessed by the blinded evaluating investigator, and willing to follow study instructions and likely to complete all required study visits

Exclusion criteria

Exclusion Criteria:

  • Brow or eyelid ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or an inability to substantially lessen upper facial rhytids, even by physically spreading them apart.
  • Facial asymmetry including, in the opinion of the investigator, significant asymmetry with active contraction or at rest of the frontalis muscle.
  • Medical condition that may increase the subject's risk of exposure to botulinum toxin, including diagnosed myasthenia gravis, Lambert-Eaton Syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.
  • Profound atrophy/excessive weakness of muscles in target areas of injection.
  • History of facial nerve palsy.
  • Infection at the injection site or systemic infection.
  • Presence of inflammation at the proposed injection site.
  • Previous cosmetic surgery to the upper face (eg, periorbital surgery, brow lift, eyelid or eyebrow surgery), tissue grafting, or tissue augmentation with silicone or fat or other permanent fillers, or planning a facial cosmetic procedure during the study period.
  • Subjects have been treated in the upper face (forehead lines, glabellar lines, crow's feet lines) within 1 year prior to the Baseline/Day 1 Visit with botulinum toxin therapy of any serotype.
  • Noncompliance with the proper washout periods for prohibited medications/procedures.
  • Subjects on topical retinoid therapy and/or topical hormone cream applied to the face, who have not been on a consistent dose regimen for at least 6 months prior to enrollment and who are unable to maintain a consistent dose regimen during the study.
  • Oral retinoid therapy within 1 year prior to study enrollment.
  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
  • Females who are pregnant, breastfeeding, or planning a pregnancy during the study.
  • Females of childbearing potential not using a reliable means of contraception.
  • Known allergy or sensitivity to the study treatment or its components.
  • Known immunization or hypersensitivity to any botulinum toxin serotype.
  • Prior exposure to or anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment).
  • Evidence of recent alcohol or drug abuse.
  • The subject has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    OLD (4 U per 0.1 mL)

    The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.5 mL.

    Drug: OnabotulinumtoxinA

  • Active comparator
    COLD (4 U per 0.02 mL group)

    The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL.

    Drug: OnabotulinumtoxinA

Interventions

  • DrugOnabotulinumtoxinA

    Injection of glabellar rhytids

    Also known as: Botox

06

What researchers measure

Primary outcomes

  1. Response Duration

    Time to return to baseline Facial Wrinkle Scale (FWS) score at maximum frown, as assessed by the blinded evaluating investigator. The Facial Wrinkle Scale (FWS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.

    Time frame: 180 days

Secondary outcomes

  1. Investigator Live Assessment (Dynamic)

    Responder rate at each visit on the Facial Wrinkle Scale (FWS) at maximum frown, as assessed by the blinded evaluating investigator. The responder rate is defined as the proportion of subjects maintaining a greater than or equal to 1 point improvement on the FWS. The Facial Wrinkle Scale (FWS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.

    Time frame: 180 days

  2. Subject Self Assessment (Dynamic)

    Responder rate at each visit on the Facial Wrinkles Scale (FWS) at maximum frown, as assessed by the subject. The Facial Wrinkle Scale (FWS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.

    Time frame: 180 days

  3. Investigator Live Assessment (At Rest)

    Responder rate at each visit on the Facial Wrinkle Scale (FWS) at rest, as assessed by the blinded evaluating investigator. The Facial Wrinkle Scale (FWS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.

    Time frame: 180 days

  4. Subject Self Assessment (At Rest)

    Responder rate at each visit on the Facial Wrinkle Scale (FWS) at rest, as assessed by the subject. The Facial Wrinkle Scale (FWS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.

    Time frame: 180 days

  5. Change from Baseline Score

    Change from baseline in mean Facial Wrinkle Scale (FWS) score at maximum frown, as assessed by the blinded evaluating investigator, at each visit. The Facial Wrinkle Scale (FWS) scale ranges from a score of 0 to 3, and a higher score indicates greater (more severe) glabellar wrinkles.

    Time frame: 180 days

  6. Change in Frontalis Function

    Percentage of subjects with weakening of frontalis muscle function using the Frontalis Function Scale (FFS) compared to baseline, as assessed by the blinded evaluating investigator, at each visit. The Frontalis Function Scale (FFS) scale ranges from a score of 0 to 3, and a higher score indicates greater reduction of forehead movement during maximal brow raise.

    Time frame: 180 days

07

Study locations

2 of 2 sites recruiting
  • Clinical Testing of Beverly Hills
    Encino, California 91436, United States
    Recruiting
  • Steve Yoelin MD
    Newport Beach, California 92663, United States
    • Steve Yoelin, MD · Contact · 747-998-5160
    • Steve Yoelin, MD · Principal investigator
    Recruiting
08

References and documents

Publications

  • Blitzer A, Binder WJ, Aviv JE, Keen MS, Brin MF. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 1997 Apr;123(4):389-92. doi: 10.1001/archoto.123.4.389. PubMed 9109785 ↗
  • Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005 Apr;31(4):414-22; discussion 422. doi: 10.1111/j.1524-4725.2005.31107. PubMed 15871316 ↗
  • Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N; BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002 Jun;46(6):840-9. doi: 10.1067/mjd.2002.121356. PubMed 12063480 ↗
  • Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004 Nov;114(6 Suppl):1S-22S. doi: 10.1097/01.PRS.0000144795.76040.D3. PubMed 15507786 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05083286
Lead sponsor
Clinical Testing of Beverly Hills
Collaborators
Allergan
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Oct 20, 2021
Primary completion
Aug 1, 2022 (estimated)
Completion
Aug 1, 2022 (estimated)
Last update
Oct 27, 2021

Study contacts

Mary Hayes
Contact
mary@clinicaltestingcenter.com
747-998-5160
John Joseph, MD
Contact
drjohnjoseph@sbcglobal.net
8186163880
John Joseph, MD
principal investigator · Clinical Testing of Beverly Hills

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Clinical Testing of Beverly Hills

Start the discussion